Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Healios KK ( (JP:4593) ) has issued an update.
Healios KK has completed regulatory consultations in Japan for its investigational ARDS treatment and is preparing for a global Phase 3 trial, REVIVE-ARDS, primarily in the United States. This agreement with the Pharmaceuticals and Medical Devices Agency (PMDA) to include Japanese patients is expected to accelerate the trial’s progress, potentially enhancing the company’s position in the global biotechnology market and offering new hope for ARDS patients worldwide.
More about Healios KK
Healios KK operates in the biotechnology industry, focusing on developing innovative treatments for critical conditions such as Acute Respiratory Distress Syndrome (ARDS). The company is engaged in creating therapies that address unmet medical needs, particularly in areas where current treatment options are limited.
YTD Price Performance: 65.54%
Average Trading Volume: 3,282,925
Technical Sentiment Signal: Sell
Current Market Cap: Yen29.73B
See more data about 4593 stock on TipRanks’ Stock Analysis page.